Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are comparing two treatments for people with non-muscle invasive bladder cancer. If you take part in this study, you will be randomly assigned to get either:
Researchers are assessing the best dose and benefit of DT2216 given with irinotecan chemotherapy in young people with cancer. DT2216 may help to kill cancer cells by blocking Bcl-xL, a protein that some cancers need to survive. Irinotecan is an anti-cancer drug that is part of the usual treatment for many cancers. Both drugs are given intravenously (by vein).
In this study, researchers want to see if the drug HER3-DXd works well against advanced melanoma. HER3-DXd is called an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them without harming other cells.
Mycosis fungoides (MF) is a disease in which lymphocytes (a type of white blood cell) become cancerous and affect the skin, causing cutaneous T-cell lymphoma. The drug bexarotene and a very low-dose form of radiation treatment called total skin electron beam (TSEB) radiotherapy are each used individually to treat MF; this study is evaluating the safety of their use together. Researchers think that since bexarotene takes up to three months to relieve symptoms, combining it with TSEB could stabilize or improve MF and reduce symptoms, including itching.
Researchers want to find the best dose of AJ1-11095 to treat myelofibrosis. The people in this study have myelofibrosis that came back or got worse after treatment.
Researchers are comparing IMA203 cellular therapy with standard treatment in people with melanoma of the skin. Their melanoma is inoperable (cannot be surgically removed) or metastatic (has spread) and keeps growing despite treatment.
Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:
In this study, researchers want to learn if tigilanol tiglate is safe and works well against advanced soft tissue sarcoma. When injected into a tumor, tigilanol tiglate stops the blood supply to the cancer, which starves the tumor of nutrients. It may also make the immune system target and kill cancer cells.
Researchers want to find the best dose of xaluritamig to treat prostate cancer. The people in this study have prostate cancer that has not metastasized (spread) but keeps growing after treatment. Their doctors believe their cancers may respond to hormonal therapies that lower cancer-fueling testosterone. This type of cancer is called non-metastatic castration-sensitive prostate cancer.
